BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 20039297)

  • 1. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes.
    Setiady YY; Coccia JA; Park PU
    Eur J Immunol; 2010 Mar; 40(3):780-6. PubMed ID: 20039297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial depletion of CD69low-expressing natural regulatory T cells with the anti-CD25 monoclonal antibody PC61.
    McNeill A; Spittle E; Bäckström BT
    Scand J Immunol; 2007 Jan; 65(1):63-9. PubMed ID: 17212768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD25 mAb administration prevents spontaneous liver transplant tolerance.
    Li W; Carper K; Liang Y; Zheng XX; Kuhr CS; Reyes JD; Perkins DL; Thomson AW; Perkins JD
    Transplant Proc; 2006 Dec; 38(10):3207-8. PubMed ID: 17175224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma.
    Johnson BD; Jing W; Orentas RJ
    J Immunother; 2007; 30(2):203-14. PubMed ID: 17471167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T cells are necessary for implantation and maintenance of early pregnancy but not late pregnancy in allogeneic mice.
    Shima T; Sasaki Y; Itoh M; Nakashima A; Ishii N; Sugamura K; Saito S
    J Reprod Immunol; 2010 Jun; 85(2):121-9. PubMed ID: 20439117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.
    He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X
    Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
    Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
    Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells.
    Xia G; He J; Zhang Z; Leventhal JR
    Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.
    Qu Y; Zhang B; Zhao L; Liu G; Ma H; Rao E; Zeng C; Zhao Y
    Transpl Immunol; 2007 Apr; 17(3):153-61. PubMed ID: 17331841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation.
    Wang Z; Xiao L; Shi BY; Qian YY; Bai HW; Chang JY; Cai M
    Transpl Immunol; 2008 Apr; 19(1):69-73. PubMed ID: 18346640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.
    Teng MW; Swann JB; von Scheidt B; Sharkey J; Zerafa N; McLaughlin N; Yamaguchi T; Sakaguchi S; Darcy PK; Smyth MJ
    Cancer Res; 2010 Apr; 70(7):2665-74. PubMed ID: 20332236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
    Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
    Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
    Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
    Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significantly enhanced frequency of functional CD4+CD25+Foxp3+ T regulatory cells in therapeutic dose aspirin-treated mice.
    Javeed A; Zhang B; Qu Y; Zhang A; Sun C; Zhang L; Liu J; Zeng C; Zhao Y
    Transpl Immunol; 2009 Mar; 20(4):253-60. PubMed ID: 19146957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination of CD4+ CD25+ regulatory T cell and costimulatory pathway blockade inhibits acute rejection after liver transplantation: experiment with rats].
    Shi LB; Zhang HW; Peng CH
    Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(14):942-6. PubMed ID: 17650415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Foxp3+ regulatory T cells in liver transplant tolerance.
    Li W; Carper K; Zheng XX; Kuhr CS; Reyes JD; Liang Y; Perkins DL; Thomson AW; Perkins JD
    Transplant Proc; 2006 Dec; 38(10):3205-6. PubMed ID: 17175223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
    Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
    Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice.
    Couper KN; Blount DG; de Souza JB; Suffia I; Belkaid Y; Riley EM
    J Immunol; 2007 Apr; 178(7):4136-46. PubMed ID: 17371969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.